[Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic]

MLA

I, Spicka, et al. “[Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma--the First Experience in the Czech Republic].” Casopis Lekaru Ceskych, vol. 144, no. 9, Oct. 2005. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........59c336809234483106e3a94f93820467&authtype=sso&custid=ns315887.

APA

I, S., R, H., M, V., V, M., E, G., M, S., J, S., V, S., Z, A., & P, K. (2005). [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic]. Casopis Lekaru Ceskych, 144(9).

Chicago

I, Spicka, Hájek R, Vytrasová M, Maisnar V, Gregora E, Schutzova M, Straub J, Scudla V, Adam Z, and Klener P. 2005. “[Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma--the First Experience in the Czech Republic].” Casopis Lekaru Ceskych 144 (9). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........59c336809234483106e3a94f93820467&authtype=sso&custid=ns315887.